Hepatocellular Carcinoma Clinical Trial
Official title:
Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection
The investigators are trying to investigate metabolism of lactate sourced from IV Hartmann's solution in patients with hepatocellular carcinoma(HCC) compared with a control group(donation for liver transplantation) with normal liver function. Second purpose of this study is finding the predictive factor of changing metabolism of lactate sourced from IV Hartmann's solution in patients with HCC.
The liver is important in acid-base physiology and electrolyte balance. It is important
because it is a metabolically active organ which may be either a significant net producer or
consumer of hydrogen ions.
Lactate is produced in the peripheral tissues such as the muscles, skin, brain, and red
blood cells and it is metabolized predominantly in the liver and kidneys, first to pyruvate
and secondly to glucose. In the healthy liver, there is a net-uptake of lactate caused by
gluconeogenesis, and the liver exhibits a higher net lactate clearance than any other organ
anticipated to be up to 70% of the whole body clearance. Lactic acidosis will result if this
hepatic metabolism is not adequate.
Hartmann's solution, which contains 28 mmol/l of lactate and has a pH of 6.5, has been
extensively used to maintain and replace intravascular volume in a variety of anesthetic
procedures. Excessive use of saline has been observed to result in hyperchloraemic acidosis
- which has been identified as a potential side effect of saline based solutions. It has
been suggested that the use of balanced electrolyte solutions may avoid this effect.
A previous study concerned that normal saline, which does not contain lactate, might be
detrimental to liver donors because of an association with hyperchloremic metabolic
acidosis.
Metabolism of lactate sourced from IV Hartmann's solution also results in a net consumption
of H+, but as this lactate was associated with Na+, the overall result is a net bicarbonate
production. Effectively, metabolism of this lactate results in generation of an equivalent
amount of bicarbonate. The investigators are evaluating about the metabolism of lactate
sourced from IV Hartmann's solution in patients with HCC and donor for liver transplantation
(control group).
All patients underwent multiple medical assessments before surgery, including routine
laboratory tests (complete blood counts, standard liver and renal function tests,
coagulation tests, and viral serology), and electrocardiography, chest X-ray, hepatobiliary
imaging, percutaneous liver biopsy, and indocyanine green retention testing (ICG test).
Hartmann solution(Hartmann, Choongwae pharmaceutical, Seoul, Korea) solution is composed of
130 mmol/l sodium,109 mmol/l chloride, 4 mmol/l potassium,1.5 mmol/l calcium, and 28 mmol/l
lactate, and has a pH of 6.5.
Briefly, anesthesia was induced with thiopental sodium (5 mg/kg), and vecuronium(0.15
mg/kg). Endotracheal intubation was performed, and general anesthesia was maintained with
sevoflurane (2-3 vol% in 50% air and oxygen). Throughout the surgery, the patients are
monitored electrocardiography, pulse oximetry, capnography, esophageal temperature, invasive
arterial pressure (via a radial artery catheter). Fluid administration(Hartmann solution)
begin upon arrival in the operating room with 5ml/kg/hour rate. Acid-base status and
lactate, electrolyte, and hemoglobin concentrations were assessed immediately and 2 hour
after induction of anesthesia. The infusion rate of fluid is 5ml/kg/hour. The reasons of
that rate are intravenous crystalloid administration has been restricted during hepatic
dissection at the request of the surgeon and the investigators considered about the
requirement of fluid loss. Mean arterial blood pressure >60mmHg and urine output >0.5
ml/kg/h were maintained during anesthesia. When mean arterial blood pressure was < 60 mmHg,
the volume of fluid administered was increased initially and/or intravenous ephedrine (5-10
mg) was injected, as appropriate. If it cannot maintain the hemodynamic stability and need
more fluid administration, the investigators manage other fluid administration or
inotropics, and the case is withdrawn.
Duration of 2 hours, volumes of Hartmann solution and the result of arterial blood gas
analysis (Acid-base status and lactate, electrolyte, and hemoglobin concentrations were
assessed immediately and 2 hour after induction of anesthesia) is recorded.
The investigators compare the change of lactate level of patients with HCC and a control
group( donation for liver transplantation) with normal liver function. After evaluating
metabolism of exogenous lactate, the investigators are trying to find the predictive factor
(among liver profile lab, MELD score, INR, functional liver volume, ICG test) of changing
metabolism of lactate sourced from IV Hartmann's solution in patients with HCC.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |